Morphological diagnosis of urothelial neoplasms

Journal of Clinical Pathology

Volumn 61, Issue 1, 2008, Pages 3-10

  Montironi, Rodolfo ^a,d   Mazzucchelli, R ^a   Scarpelli, M ^a   Lopez Beltran, A ^b   Cheng, L ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Universidad de Cordoba   (Spain)

^c INDIANA UNIVERSITY   (United States)

^d Section of Pathological Anatomy and Histopathology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENIGN TUMOR; CANCER CELL; CANCER CLASSIFICATION; CANCER STAGING; CARCINOMA IN SITU; CELL HYPERPLASIA; CELL INVASION; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL EVALUATION; CLINICAL FEATURE; CYSTITIS; CYTOLOGY; DYSPLASIA; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; LAMINA PROPRIA; PAPILLARY CARCINOMA; PAPILLOMA; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT TUMOR; UROTHELIUM; WORLD HEALTH ORGANIZATION; BLADDER TUMOR; CLASSIFICATION; PATHOLOGY; PRECANCER;

CARCINOMA IN SITU; CARCINOMA, PAPILLARY; HUMANS; PAPILLOMA; PRECANCEROUS CONDITIONS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 38449112383     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.049312     Document Type: Review

References (49)

1. Sauter G, Algaba F, Amin MB, et al. Tumours of the urinary system. In: Epstein JI, Eble JN, Sesterhenn I, Sauter G, eds. World Health Organization Classification of Tumours. Pathology and genetics: tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004:89-157.
2. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Irrt J Surg Pathol 2005;13:143-53.
3. Epstein JI, Amin MB, Reuter VE. In: Epstein JI, ed. Urinary bladder biopsy interpretation. Philadelphia, PA: Lippincott Williams & Wilkins, 2004.
4. Jost SP, Gosling JA, Dixon JS. The morphology of normal human bladder urothelium. J Anat 1989;167:103-15.
5. Kunju LP, Lee CT, Montie J, et al. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int 2005;55:248-54.
6. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000;13:1315-23.
7. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non neoplastic urothelium. An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25:1074-8.
8. Mallofre C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003;16:187-91.
9. Lopez-Beltran A, Cheng L, Andersson L, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002;440:3-11.
10. Nagy GH, Frable WJ, Murphy WM. The classification of premalignant urothelial abnormalities. Pathol Ann 1982;17:219-33.
11. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
12. Murphy WM, Soloway MS. Urothelial dysplasia. J Urol 1982;127:849-54.
13. Zuk RJ, Rogers HS, Martin JE, et al. Clinicopathological importance of primary dysplasia of bladder. J Clin Pathol 1988;41:1277-80.
14. Cheng L, Cheville JC, Neumann RM, et al. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-7.
15. Lopez-Beltran A, Luque RJ, Moreno A, et al. The pagetoid variant of bladder urothelial carcinoma in situ. A clinicopathological study of 11 cases. Virchows Arch 2002;441:148-53.
16. Murphy WM, Soloway MS, Finebaum PJ. Pathologic changes associated with topical chemotherapy for superficial bladder cancer. J Urol 1980;126:461-5.
17. Koss LG. Diagnostic cytology and its histopathologic basis, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 1992.
18. Harnden P, Eardley I, Joyce AD, et al. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870- 5.
19. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27:1-10.
20. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92.
21. Farrow GM, Utz DC. Observations on microinvasive transitional cell carcinoma of the urinary bladder. Clin Oncol 1982;1:609-15.
22. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinomas in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001;25:356-62.
23. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns. A discussion of patterns of invasion and problems associated with carcinoma-in-situ. J Urol 1976;116:575-80.
24. Amin MB, McKenney JK. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anat Pathol 2002;9:222-32.
25. Cheng L, Darson M, Cheville JC. Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer 1999;86:2098- 101.
26. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003;17:623-9.
27. Taylor DC, Bhagavan BS, Larsen MP, et al. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 1996;20:1481-8.
28. Hartmann A, Moser K, Kriegmair M. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-7.
29. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999;86:2102-8.
30. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002;60:315-19.
31. Alvarez Kindelan J, Lopez Beltran A, Anglada Curado F, et al. Clinico-pathologic differences between bladder neoplasm with low malignant potential and low-grade carcinoma. Actas Urol Esp 2001;25:645-50.
32. Herr HW. Tumor progression and survival of patients with high-grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:79-80.
33. Saika T, Tsushima T, Nasu Y, et al. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Jpn J Clin Oncol 2002;32:461-5.
34. Volmar KE, Chan TY, De Marzo AM, et al. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol 2003;27:1243-52.
35. Melicow M, Hollowell J. Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system. Discussion of 30 cases. J Urol 1952:68:763-71.
36. Humphrey PA. Urinary bladder pathology 2004: an update. Ann Diagn Pathol 2004;6:380-9.
37. Caro DJ, Tessler A. Inverted papilloma of the bladder: a distinct urological lesion. Cancer 1978;42:708-13.
38. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997;21:1057-68.
39. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002;441:109-16.
40. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105-8.
41. Harnden P. A critical appraisal of the classification of the urothelial tumours: time for a review of the evidence and a radical change? BJU Int 2007;99:723-5.
42. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007;51:889- 97.
43. Lopez Beltran A, Bassi P, Pavone-Macaluso M, et al. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 2004;45:257-66.
44. Jimenez RE, Keane TE, Hardy HT, et al. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol 2000;7:13-25.
45. Philip AT, Amin MB, Tamboli P, et al. Intravesical adipose tissue: a quantitative study of its presence and location with implications for therapy and prognosis. Am J Surg Pathol 2000;24:1286-90.
46. Angulo JC, Lopez JI, Grignon D, et al. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995;45:47-53.
47. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543-8.
48. Cheng L, Weaver AL, Neumann RM, et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999;86:1035-43.
49. Jimenez RE, Gheiler E, Oskanian P, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000;24:980-7.